ArdorComm Media Group

Contact Us
Tuesday, May 19, 2026 4:55 AM
logo
Menu
logo

Type 2 Diabetes

India Tightens Oversight on GLP-1 Drugs Amid Rising Misuse Concerns

/ Governance Community

The Government of India has issued a comprehensive advisory on GLP-1 drugs, cautioning against their inappropriate use while acknowledging their growing role in managing type 2 diabetes and obesity. With demand surging—particularly for weight loss—authorities are stepping up regulation to safeguard public health. GLP-1 (Glucagon-Like Peptide-1) medications are designed to regulate blood sugar levels by enhancing insulin secretion and reducing excess glucose. They also aid in weight management by slowing digestion and curbing appetite, making them increasingly sought after beyond their primary medical purpose. However, officials have emphasized that these are not lifestyle or wellness products, but potent prescription drugs that must only be used under medical supervision. The advisory comes in response to concerns over their easy availability through online platforms and wellness clinics. Health authorities have warned that unsupervised use may lead to adverse effects, including gastrointestinal problems, hormonal disturbances, and other complications. Experts underline that these drugs are not suitable for everyone and should never be used casually for weight loss. As per the guidelines, only qualified specialists—such as endocrinologists, internal medicine physicians, and cardiologists—are authorised to prescribe GLP-1 drugs. Over-the-counter sale is strictly prohibited, and individuals are strongly advised against purchasing them without a valid prescription. Regulatory bodies, including the Drug Controller General of India (DCGI) and State Drug Controllers, have intensified inspections across pharmacies, clinics, and digital platforms. Any violations—ranging from illegal sales to misuse—will invite stringent penalties, including licence suspension and legal action. The government’s move comes at a time when the popularity of these drugs is rapidly increasing, especially as quick weight-loss solutions. Authorities aim to ensure that genuine patients retain access while preventing unsafe and unregulated usage. The advisory reinforces a critical message: GLP-1 drugs are powerful medical treatments, not shortcuts for weight loss. Responsible use, guided by medical expertise and supported by strict regulation, will be essential to ensuring patient safety in India. Source: India Today

India Tightens Oversight on GLP-1 Drugs Amid Rising Misuse Concerns Read More »

Diabetes Driving India’s Silent Liver Disease Crisis, Study Warns

/ Health & Wellness Community

A groundbreaking study has revealed that Type 2 diabetes is emerging as a major cause of advanced liver disease in India, often progressing unnoticed until it becomes life-threatening. Published in The Lancet, the DiaFib-Liver Study is the largest real-world research of its kind in a developing country, highlighting the liver as a critical yet overlooked organ at risk among diabetic patients. The study, which assessed 9,202 adults across 27 healthcare centres, found that nearly 25% of patients had significant liver fibrosis, while about 14% had advanced disease. Alarmingly, around 5% had already reached a stage suggestive of cirrhosis—despite showing no obvious symptoms. Experts note a shift in the primary causes of severe liver conditions, with diabetes and obesity now surpassing viral infections like Hepatitis B and C. The underlying mechanism involves fat accumulation in the liver, leading to insulin resistance, chronic inflammation, and eventual scarring. Interestingly, the research also challenges the belief that liver disease primarily affects overweight individuals. Cases were observed even among lean patients, with a phenomenon termed “burnt-out” liver disease—where fat diminishes as fibrosis worsens—making detection even more difficult. Given that liver damage often remains silent until advanced stages, researchers emphasize the need for improved screening. They recommend tools like the FIB-4 score, derived from routine blood tests, and FibroScan imaging for early detection, instead of relying solely on ultrasounds. Encouragingly, the study highlights that early-stage liver damage can be reversed. A 5% reduction in body weight may reverse fibrosis in many cases, while a 10% reduction can significantly slow disease progression. With India home to over 10 crore diabetics and millions more at risk, integrating liver health checks into diabetes care programs could be key to preventing a large-scale health crisis. Source: TNN

Diabetes Driving India’s Silent Liver Disease Crisis, Study Warns Read More »

Study in India Reveals Link Between Air Pollution and Type 2 Diabetes Risk

/ Health & Wellness Community
News on Health

Air pollution in India has been linked to an increased risk of type 2 diabetes, as revealed in a groundbreaking study published in the BMJ Open Diabetes Research and Care journal. The study, the first of its kind in India, was conducted in Delhi and Chennai, and it found that exposure to elevated levels of fine pollution particles (PM2.5) in the air, which are 30 times thinner than a strand of hair, is associated with higher blood sugar levels and an elevated incidence of type 2 diabetes. While the health impacts of fine particulate matter are known for cardiovascular and cardiometabolic diseases, this study sought to provide evidence from regions with high air pollution levels like India, where noncommunicable diseases are a significant burden. The research team, which included scientists from the Centre for Chronic Disease Control in New Delhi, followed a group of over 12,000 men and women from 2010 to 2017, regularly measuring their blood sugar levels. They also utilized satellite data and air pollution exposure models to assess air quality in the participants’ localities during that period. The results demonstrated that exposure to PM2.5 for just one month led to increased blood sugar levels, and prolonged exposure for a year or more elevated the risk of diabetes. Additionally, for every 10 micrograms per cubic meter (μg/m3) increase in the annual average PM2.5 levels in Delhi and Chennai, the risk of diabetes rose by 22 percent. The study addressed a significant research gap in South Asia, where diabetes is a major health concern, by providing robust exposure assessment and longitudinal data in this population. It underscores the need for tailored, population-specific policies to combat the high diabetes prevalence by reducing ambient air pollution. The research team, which also included scientists from the Public Health Foundation of India, Harvard University, Emory University, the All India Institute of Medical Sciences, and the Madras Diabetes Research Foundation, emphasized the importance of region-specific measures to achieve meaningful public health improvements at the population level.

Study in India Reveals Link Between Air Pollution and Type 2 Diabetes Risk Read More »